Home / Health / FDA Okays New Pancreatic Cancer Drug Rasonque
FDA Okays New Pancreatic Cancer Drug Rasonque
26 Aug
Summary
- FDA approved Rasonque for advanced pancreatic cancer.
- Rasonque doubles overall survival in clinical trials.
- This approval offers a new targeted therapy option.
The U.S. Food and Drug Administration (FDA) has granted approval for Rasonque (daraxonrasib), a novel RAS inhibitor developed by Revolution Medicines. This once-daily tablet is indicated for adult patients diagnosed with metastatic pancreatic adenocarcinoma who have previously undergone at least one systemic therapy or are unsuitable for multiagent treatment.
Rasonque is engineered to target multiple forms of RAS, a critical factor in pancreatic adenocarcinoma tumor development. Its approval was accelerated, arriving 6.5 months ahead of the user fee deadline, underscoring its importance for a serious and life-threatening illness.
The FDA's decision was informed by a multicenter clinical trial involving 500 adults. Participants treated with Rasonque experienced a median overall survival of 13.2 months, a substantial improvement over the 6.7 months seen with standard chemotherapy.
This marks a significant milestone for Revolution Medicines, providing a much-needed targeted treatment avenue for patients battling metastatic pancreatic adenocarcinoma. The drug also received FDA Breakthrough Therapy, Orphan Drug designations, and Priority Review status, highlighting its therapeutic potential.
